RA Phase 2 Trial Results Presented At ACR Annual Meeting
Filed with ASX · · 5 pages · English
In the deck
Story so far
Earlier from Mesoblast
- End-Stage Heart Failure Trial Completes Enrollment
- Mesoblast Corporate Updates at Healthcare Conferences
- Retail Entitlement Offer
- Underwritten A$50.7M Raise Closes Institutional Allocation
- Fully Underwritten A$50.7 Million Entitlement Offer
Later from Mesoblast
- Mesoblast Provides Corporate Update and Q1 Financial Results
- Response to ASX Aware Letter Query
- MSB Named Global Technology Leader In Cell Therapy Industry
- Mesoblast Grants TiGenix License For Treatment of Fistulae
- Mesoblasts P3 GVHD Trial Completes Enrollment
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast